Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Uwe Klaus Zettl

Showing results (1-10 of 71) with videos related to

Pageof 8
Sort By:
Diagnostics (Basel, Switzerland)|June 12, 2026
Bayes at the Bedside: Biomarkers in Situations of Clinical UncertaintyUwe Klaus Zettl, Michael Hecker
Current Pharmaceutical Design|July 29, 2021
Polypharmacy in Chronic Neurological Diseases: Multiple Sclerosis, Dementia and Parkinson's DiseaseNiklas Frahm, Michael Hecker, Uwe Klaus Zettl
Scientific Reports|March 8, 2019
Multi-drug use among patients with multiple sclerosis: A cross-sectional study of associations to clinicodemographic factorsNiklas Frahm, Michael Hecker, Uwe Klaus Zettl
Plos One|January 25, 2019
Polypharmacy in outpatients with relapsing-remitting multiple sclerosis: A single-center studyNiklas Frahm, Michael Hecker, Uwe Klaus Zettl
Pharmaceutics|January 26, 2024
Update and Application of a Deep Learning Model for the Prediction of Interactions between Drugs Used by Patients with Multiple SclerosisMichael Hecker, Niklas Frahm, Uwe Klaus Zettl
Autoimmunity Reviews|June 14, 2015
Molecular biomarkers in cerebrospinal fluid of multiple sclerosis patientsBrit Fitzner, Michael Hecker, Uwe Klaus Zettl
Biology of Sex Differences|May 29, 2019
Polypharmacy in patients with multiple sclerosis: a gender-specific analysisNiklas Frahm, Michael Hecker, Uwe Klaus Zettl
Expert Opinion on Drug Safety|January 23, 2020
Polypharmacy among patients with multiple sclerosis: a qualitative systematic reviewNiklas Frahm, Michael Hecker, Uwe Klaus Zettl
Aging and Disease|August 3, 2021
Systematic Review of Studies on Telomere Length in Patients with Multiple SclerosisJan Bühring, Michael Hecker, Brit Fitzner, et al.
Scientific Data|July 25, 2018
Microarray data of transcriptome shifts in blood cell subsets during S1P receptor modulator therapyDirk Koczan, Brit Fitzner, Uwe Klaus Zettl, et al.
Pageof 8

Showing results (1-10 of 71) with videos related to

Sort By:
Pageof 8
Diagnostics (Basel, Switzerland)|June 12, 2026
Bayes at the Bedside: Biomarkers in Situations of Clinical UncertaintyUwe Klaus Zettl, Michael Hecker
Current Pharmaceutical Design|July 29, 2021
Polypharmacy in Chronic Neurological Diseases: Multiple Sclerosis, Dementia and Parkinson's DiseaseNiklas Frahm, Michael Hecker, Uwe Klaus Zettl
Scientific Reports|March 8, 2019
Multi-drug use among patients with multiple sclerosis: A cross-sectional study of associations to clinicodemographic factorsNiklas Frahm, Michael Hecker, Uwe Klaus Zettl
Plos One|January 25, 2019
Polypharmacy in outpatients with relapsing-remitting multiple sclerosis: A single-center studyNiklas Frahm, Michael Hecker, Uwe Klaus Zettl
Pharmaceutics|January 26, 2024
Update and Application of a Deep Learning Model for the Prediction of Interactions between Drugs Used by Patients with Multiple SclerosisMichael Hecker, Niklas Frahm, Uwe Klaus Zettl
Autoimmunity Reviews|June 14, 2015
Molecular biomarkers in cerebrospinal fluid of multiple sclerosis patientsBrit Fitzner, Michael Hecker, Uwe Klaus Zettl
Biology of Sex Differences|May 29, 2019
Polypharmacy in patients with multiple sclerosis: a gender-specific analysisNiklas Frahm, Michael Hecker, Uwe Klaus Zettl
Expert Opinion on Drug Safety|January 23, 2020
Polypharmacy among patients with multiple sclerosis: a qualitative systematic reviewNiklas Frahm, Michael Hecker, Uwe Klaus Zettl
Aging and Disease|August 3, 2021
Systematic Review of Studies on Telomere Length in Patients with Multiple SclerosisJan Bühring, Michael Hecker, Brit Fitzner, et al.
Scientific Data|July 25, 2018
Microarray data of transcriptome shifts in blood cell subsets during S1P receptor modulator therapyDirk Koczan, Brit Fitzner, Uwe Klaus Zettl, et al.
Pageof 8